Anti-TNF mAbs, JAKi & anti-IL17 Rx appear protective against anterior Uveitis in AxSpA pts. Network Metanalysis of 44 trials, AU IR -TNF mAb: 4.1, ETN: 5.4, IL17i: 2.8, JAKi: 1.5, & placebo: 10.8. AU risk: TNFi < JAKi < IL-17i < ETN << PBO https://t.co/uRYKmtUdsZ https://t.co/5XdBVDfgYV
Links:
The incidence of uveitis in patients with axial spondylarthritis treated with b…
https://bit.ly/3H6MyVW
Jan-03-2024
